An Open-label, Randomized, Phase 3 Study of Nivolumab, Nivolumab combined with Ipilimumab, or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy

Trial Profile

An Open-label, Randomized, Phase 3 Study of Nivolumab, Nivolumab combined with Ipilimumab, or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2016 Planned End Date changed from 1 Oct 2016 to 31 Jul 2016.
    • 03 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top